Han Cong

July 2014 to October 2015 Jiangsu Hongyuan Law Office
November 2015 – present Jiangsu JC Master Law Office

Partner at JC Master Law Office
Master of Laws, Nanjing Normal University

Attorney Han Cong primarily practices in post-investment fund management, civil and commercial dispute resolution, and corporate governance, with extensive experience in these areas. He has represented investment offices such as Yida Capital, Lianquan Guoxin, Nan Venture Capital, Qilin Venture Capital, Xi Venture Capital, Jinyu Maowu, Shanghai Zhonghuijin, and others in handling their investment exit matters, achieving favorable outcomes.
Attorney Han Cong has handled a number of representative cases, including but not limited to: the equity‑repurchase dispute between Jiangsu GaoTou Ningtai Venture Investment Partnership (Limited Partnership) and Lianyungang Guanyun Renji Hospital et al.; the equity‑repurchase dispute between Jiangsu Talent Innovation and Entrepreneurship Investment Partnership (Limited Partnership) and Li Nanjie et al.; the equity‑repurchase dispute between Nanjing Industrial Development Fund Co., Ltd. and Shen Meng et al.; a series of equity‑repurchase disputes involving JinYu Maowu Investment Management Co., Ltd. and Jiangsu Sanxi Technology Co., Ltd. et al.; the equity‑repurchase dispute between Nanjing Chuangyi Haohui Venture Investment Partnership (Limited Partnership) and Zhang Chi et al.; the equity‑repurchase dispute between Nanjing Chuangyi Haohui Venture Investment Partnership (Limited Partnership) and Zhao Wei et al.; the equity‑repurchase dispute between Wuxi Hechuang High‑Tech Phase II Equity Investment Partnership (Limited Partnership) and Qin Jiayi et al.; the equity‑repurchase dispute between Nanjing Qilin High‑Tech Zone Venture Investment Fund Partnership (Limited Partnership) and Zhang Liang et al.; the equity‑repurchase dispute between Jiangsu SME Development Fund (Limited Partnership) and Liu Shunlong et al.; the equity‑repurchase dispute between Jiangsu Yida M&A Growth Equity Investment Fund (Limited Partnership) and Shi Jijun et al.; the equity‑repurchase dispute between Suzhou Yida Innovation and Entrepreneurship Investment Partnership (Limited Partnership) and Shi Jijun et al.; the equity‑repurchase dispute between Jiangsu Lianquan Guoxin New Energy Industry Investment Fund Partnership (Limited Partnership) and Kang Yong et al.; the equity‑repurchase dispute between Nanjing Qinhuai Industrial Guidance Fund Partnership (Limited Partnership) and Fu Jianling et al.; the equity‑repurchase dispute between Nanjing Jiangbei Medical Innovation Industry Fund (Limited Partnership) and Zhou Liang et al.; the equity‑repurchase dispute between Kunshan Fumao Venture Investment Partnership (Limited Partnership) and Zhang Jingbin et al.; the equity‑repurchase dispute between Jiangsu New Materials Industry Venture Investment Enterprise (Limited Partnership) and Jiang Wenxian et al.; the equity‑repurchase dispute between Tibet Jinmao Jingxin Venture Investment Co., Ltd. and Zhang Liping et al.; the equity‑repurchase dispute between Nanjing JinTou Health Industry Investment Enterprise (Limited Partnership) and Zhu Mingfei et al.; the equity‑repurchase dispute between Wuxi Jinmao Huishan Medical and Health Industry Investment Partnership (Limited Partnership) and Deng Xiaoming et al.; the equity‑repurchase dispute between Taicang Jinmao Biopharmaceutical Venture Investment Enterprise (Limited Partnership) and He Aimin et al.; the equity‑repurchase dispute between Jiangsu Lianquan Jinmao New Materials Venture Investment Partnership (Limited Partnership) and Zhuang Ming et al.; the equity‑repurchase dispute between Jiangsu New Materials Industry Venture Investment Enterprise (Limited Partnership) and Chen Long et al.; the equity‑repurchase dispute between Jiangsu Jinmao Low‑Carbon Industry Venture Investment Co., Ltd. and Pan Dekou et al.; a series of performance‑compensation disputes involving Jinling Pharmaceutical Co., Ltd. and Huzhou Guoxin Materials Co., Ltd. et al.; the performance‑compensation dispute between Wang Junxia and Fujian Adier Jewelry Industrial Co., Ltd.; and the share‑custody dispute between Wuxi Kewenning Trading Co., Ltd. and Jiangsu Zhongmei Mining Equipment Co., Ltd. et al., among others.
Attorney Han Cong currently serves as the long-term legal counsel to numerous enterprises, including Jinling Pharmaceutical Co., Ltd., Jiangsu Phoenix Xinhua Printing Group Co., Ltd., Baosheng Technology Innovation Co., Ltd., Jiangsu Xinguanglian Optoelectronics Co., Ltd., Jiangsu Xinguanglian Technology Co., Ltd., and Jinyu Maowu Investment Management Co., Ltd.